125 related articles for article (PubMed ID: 38455372)
1. Risk stratification for radioactive iodine refractoriness using molecular alterations in distant metastatic differentiated thyroid cancer.
Mu Z; Zhang X; Liang D; Fang J; Chen G; Guo W; Sun D; Sun Y; Kai Z; Huang L; Liang J; Lin Y
Chin J Cancer Res; 2024 Feb; 36(1):25-35. PubMed ID: 38455372
[TBL] [Abstract][Full Text] [Related]
2. Characterizing Genetic Alterations Related to Radioiodine Avidity in Metastatic Thyroid Cancer.
Mu Z; Zhang X; Sun D; Sun Y; Shi C; Ju G; Kai Z; Huang L; Chen L; Liang J; Lin Y
J Clin Endocrinol Metab; 2024 Apr; 109(5):1231-1240. PubMed ID: 38060243
[TBL] [Abstract][Full Text] [Related]
3. Risk Stratification Using a Novel Genetic Classifier Including
Jung CK; Jung SH; Jeon S; Jeong YM; Kim Y; Lee S; Bae JS; Chung YJ
Thyroid; 2020 Nov; 30(11):1589-1600. PubMed ID: 32326836
[No Abstract] [Full Text] [Related]
4. Radioactive iodine refractoriness in Middle Eastern differentiated thyroid cancer: clinical outcome and risk factor analysis.
Parvathareddy SK; Siraj AK; Siraj N; Ahmed SO; Al-Rasheed M; Qadri Z; Siddiqui K; Al-Sobhi SS; Al-Dayel F; Al-Kuraya KS
Front Endocrinol (Lausanne); 2024; 15():1326976. PubMed ID: 38812819
[TBL] [Abstract][Full Text] [Related]
5. Fusion Oncogenes in Patients With Locally Advanced or Distant Metastatic Differentiated Thyroid Cancer.
Ju G; Sun Y; Wang H; Zhang X; Mu Z; Sun D; Huang L; Lin R; Xing T; Cheng W; Liang J; Lin YS
J Clin Endocrinol Metab; 2024 Jan; 109(2):505-515. PubMed ID: 37622214
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological features of differentiated thyroid carcinoma as predictors of the effects of radioactive iodine therapy.
Liu W; Jiang B; Xue J; Liu R; Wei Y; Li P
Ann Diagn Pathol; 2024 Apr; 69():152243. PubMed ID: 38128440
[TBL] [Abstract][Full Text] [Related]
7. Highly Concordant Key Genetic Alterations in Primary Tumors and Matched Distant Metastases in Differentiated Thyroid Cancer.
Sohn SY; Park WY; Shin HT; Bae JS; Ki CS; Oh YL; Kim SW; Chung JH
Thyroid; 2016 May; 26(5):672-82. PubMed ID: 26971368
[TBL] [Abstract][Full Text] [Related]
8. Clinical relevance of gene mutations and rearrangements in advanced differentiated thyroid cancer.
Nannini M; Repaci A; Nigro MC; Colapinto A; Vicennati V; Maloberti T; Gruppioni E; Altimari A; Solaroli E; Lodi Rizzini E; Monari F; De Leo A; Damiani S; Pagotto U; Pantaleo MA; de Biase D; Tallini G
ESMO Open; 2023 Dec; 8(6):102039. PubMed ID: 37879236
[TBL] [Abstract][Full Text] [Related]
9. Clinical, Pathological, and Molecular Profiling of Radioactive Iodine Refractory Differentiated Thyroid Cancer.
Shobab L; Gomes-Lima C; Zeymo A; Feldman R; Jonklaas J; Wartofsky L; Burman KD
Thyroid; 2019 Sep; 29(9):1262-1268. PubMed ID: 31319763
[No Abstract] [Full Text] [Related]
10. Non-Iodine-Avid Disease Is Highly Prevalent in Distant Metastatic Differentiated Thyroid Cancer With Papillary Histology.
Soe MH; Chiang JM; Flavell RR; Khanafshar E; Mendoza L; Kang H; Liu C
J Clin Endocrinol Metab; 2022 Jul; 107(8):e3206-e3216. PubMed ID: 35556126
[TBL] [Abstract][Full Text] [Related]
11. Predictive Value of Clinical and Pathological Characteristics for Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma: A 16-year Retrospective Study.
Chai J; Zhang R; Zheng W; Zhang G; Jia Q; Tan J; Meng Z; Wang R
Front Endocrinol (Lausanne); 2022; 13():930180. PubMed ID: 35846335
[TBL] [Abstract][Full Text] [Related]
12. IGF2 is a potential factor in RAI-refractory differentiated thyroid cancer.
Crezee T; Tesselaar MH; Jaeger M; Rabold K; Corver WE; Morreau H; Van Engen-Van Grunsven ACH; Smit JWA; Netea-Maier RT; Plantinga TS
Oncol Lett; 2021 Aug; 22(2):590. PubMed ID: 34149901
[TBL] [Abstract][Full Text] [Related]
13. Clinical Outcomes of Radioactive Iodine Redifferentiation Therapy in Previously Iodine Refractory Differentiated Thyroid Cancers.
Toro-Tobon D; Morris JC; Hilger C; Peskey C; Durski JM; Ryder M
Thyroid; 2024 Jan; 34(1):70-81. PubMed ID: 37917101
[No Abstract] [Full Text] [Related]
14. Identification of Radioactive Iodine Refractory Differentiated Thyroid Cancer.
Mu ZZ; Zhang X; Lin YS
Chonnam Med J; 2019 Sep; 55(3):127-135. PubMed ID: 31598469
[TBL] [Abstract][Full Text] [Related]
15. Redifferentiation of BRAF V600E-Mutated Radioiodine Refractory Metastatic Papillary Thyroid Cancer After Treatment With Dabrafenib and Trametinib.
Jafri S; Yaqub A
Cureus; 2021 Aug; 13(8):e17488. PubMed ID: 34595070
[TBL] [Abstract][Full Text] [Related]
16. Ultrasound characteristics of cervical lesions in patients with radioiodine refractory differentiated thyroid cancer: A strobe-compliant article.
Gao L; Lin Y; Jiang Y; Li H; Gao Q; Xi X; Wang Y; Yang X; Lai X; Zhu S; Zhang X; Zhao R; Zhang B
Medicine (Baltimore); 2019 Nov; 98(45):e17876. PubMed ID: 31702656
[TBL] [Abstract][Full Text] [Related]
17. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.
Iravani A; Solomon B; Pattison DA; Jackson P; Ravi Kumar A; Kong G; Hofman MS; Akhurst T; Hicks RJ
Thyroid; 2019 Nov; 29(11):1634-1645. PubMed ID: 31637953
[No Abstract] [Full Text] [Related]
18. Clinical role of 18F-FDG PET/CT for detection of radioactive iodine refractory differentiated thyroid cancer.
Tang X; Shi L; Zhao Z; Wang J; Yang R; Huang Y; Tang J; Chen Z; Wang F
Medicine (Baltimore); 2023 Jun; 102(24):e33878. PubMed ID: 37327310
[TBL] [Abstract][Full Text] [Related]
19. Antitumour effects of apatinib in progressive, metastatic differentiated thyroid cancer (DTC).
Shi L; You Q; Wang J; Wang H; Li S; Tian R; Yao X; Wu W; Zhang L; Wang F; Lin Y; Li S
Endocrine; 2022 Oct; 78(1):68-76. PubMed ID: 35767182
[TBL] [Abstract][Full Text] [Related]
20. TERT promoter mutation in primary papillary thyroid carcinoma lesions predicts absent or lower
Meng Z; Matsuse M; Saenko V; Yamashita S; Ren P; Zheng X; Jia Q; Tan J; Li N; Zheng W; Zhao L; Mitsutake N
IUBMB Life; 2019 Jul; 71(7):1030-1040. PubMed ID: 31026111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
